About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
Our Pipeline
AMPK activators: SCY-770
Antifungal triterpenoids: SCY-247
Autosomal Dominant Polycystic Kidney Disease
Life-threatening Fungal Infections
Publications and Presentations
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
April 2025
Assessment of
in vitro
activity of the new triterpenoid antifungal, SCY-247, against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024
ESCMID, April 2025
September 2024
SCY-247, A SECOND-GENERATION TRITERPENOID ANTIFUNGAL DEMONSTRATES BROAD TISSUE DISTRIBUTION AND EFFICACY IN MURINE FUNGAL INFECTION MODELS
MSGERC, September 2024
April 2024
SCY-247, a Novel Second-Generation IV/Oral Triterpenoid Antifungal, Demonstrates
In vitro
Activity Against Fungal Pathogens, Including Azole-Resistant Strains of Candida and
Aspergillus
ECCMID, April 2024
April 2024
The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by
Candida glabrata
ECCMID, April 2024
January 2024
SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis
AAAM, January 2024
October 2023
SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL:
IN VITRO
ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION
IN VIVO
TIMM, October 2023
April 2023
Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with
Candida auris
(CARES)
ECCMID, April 2023
April 2023
A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy
ECCMID, April 2023
April 2023
FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp
ECCMID, April 2023
October 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI)
IDWeek
< Prev
Next >
×